INFI Infinity Pharmaceuticals, Inc. Stock Quote

INFI [NASD]

Index	-	P/E	-	EPS (ttm)	-0.53	Insider Own	0.30%	Shs Outstand	89.16M	Perf Week	106.76%
Market Cap	128.26M	Forward P/E	-	EPS next Y	-0.55	Insider Trans	0.00%	Shs Float	88.16M	Perf Month	129.66%
Income	-46.80M	PEG	-	EPS next Q	-0.09	Inst Own	44.30%	Short Float	1.59%	Perf Quarter	173.90%
Sales	2.20M	P/S	58.30	EPS this Y	21.80%	Inst Trans	-1.41%	Short Ratio	1.98	Perf Half Y	35.40%
Book/sh	-0.01	P/B	-	EPS next Y	-15.30%	ROA	-59.60%	Target Price	6.17	Perf Year	-51.12%
Cash/sh	0.67	P/C	2.27	EPS next 5Y	-	ROE	-299.00%	52W Range	0.46 - 3.89	Perf YTD	-32.00%
Dividend	-	P/FCF	-	EPS past 5Y	2.70%	ROI	-	52W High	-60.67%	Beta	2.01
Dividend %	-	Quick Ratio	4.20	Sales past 5Y	-37.00%	Gross Margin	39.70%	52W Low	232.25%	ATR	0.13
Employees	33	Current Ratio	4.20	Sales Q/Q	40.00%	Oper. Margin	-	RSI (14)	85.77	Volatility	23.80% 13.02%
Optionable	Yes	Debt/Eq	-	EPS Q/Q	-5.80%	Profit Margin	-	Rel Volume	4.36	Prev Close	1.27
Shortable	Yes	LT Debt/Eq	-	Earnings	Aug 09 AMC	Payout	-	Avg Volume	706.13K	Price	1.53
Recom	1.90	SMA20	91.16%	SMA50	106.20%	SMA200	20.99%	Volume	3,079,023	Change	20.47%

Oct-18-21

Initiated

H.C. Wainwright

Buy

Aug-02-21

Upgrade

JP Morgan

Neutral → Overweight

Jul-28-21

Upgrade

Wells Fargo

Equal Weight → Overweight

$4 → $14

Jul-07-21

Resumed

B. Riley Securities

Buy

Mar-18-21

Initiated

Truist

Buy

$12

Feb-18-21

Initiated

Piper Sandler

Overweight

Feb-05-21

Upgrade

JP Morgan

Underweight → Neutral

Jun-27-19

Initiated

Oppenheimer

Outperform

Jan-04-19

Initiated

B. Riley FBR

Buy

Nov-12-18

Downgrade

Wells Fargo

Outperform → Market Perform

Nov-12-18

Downgrade

JP Morgan

Neutral → Underweight

Oct-12-17

Upgrade

Wells Fargo

Market Perform → Outperform

Aug-10-16

Reiterated

Wedbush

Neutral

$1.25 → $1

Jun-15-16

Downgrade

Wells Fargo

Outperform → Market Perform

Jun-15-16

Downgrade

RBC Capital Mkts

Outperform → Sector Perform

$12 → $2

Jun-15-16

Downgrade

Morgan Stanley

Overweight → Equal-Weight

Jun-15-16

Downgrade

Jefferies

Buy → Hold

Jun-14-16

Downgrade

JP Morgan

Overweight → Neutral

Jun-14-16

Downgrade

JMP Securities

Mkt Outperform → Mkt Perform

Jun-14-16

Downgrade

FBR Capital

Outperform → Mkt Perform

$15 → $2

Aug-13-22 08:33AM	How Many Infinity Pharmaceuticals, Inc. (NASDAQ:INFI) Shares Do Institutions Own? Simply Wall St.
Aug-09-22 06:25PM	Infinity Pharmaceuticals (INFI) Reports Q2 Loss, Tops Revenue Estimates Zacks -8.56%
04:05PM	Infinity Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Business Update Business Wire
Aug-02-22 08:25AM	Infinity Pharmaceuticals Announces the Date of Its Second Quarter 2022 Financial Results Conference Call and Webcast Business Wire
May-19-22 01:16PM	Is Infinity Pharmaceuticals (NASDAQ:INFI) In A Good Position To Invest In Growth? Simply Wall St.
May-17-22 08:35AM	Infinity Pharmaceuticals to Participate in Upcoming H.C. Wainwright Global Investment Conference Business Wire +21.34%
May-03-22 05:45PM	Infinity Pharmaceuticals (INFI) Reports Q1 Loss, Tops Revenue Estimates Zacks +6.99%
04:05PM	Infinity Pharmaceuticals Reports First Quarter 2022 Financial Results Business Wire
Apr-26-22 08:25AM	Infinity Pharmaceuticals Announces the Date of Its First Quarter 2022 Financial Results Conference Call and Webcast Business Wire -5.85%
Apr-08-22 04:05PM	Infinity Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Business Wire
Apr-04-22 05:31PM	Even after rising 21% this past week, Infinity Pharmaceuticals (NASDAQ:INFI) shareholders are still down 64% over the past year Simply Wall St.
Mar-29-22 08:15PM	Infinity Pharmaceuticals (INFI) Reports Q4 Loss, Tops Revenue Estimates Zacks
04:05PM	Infinity Pharmaceuticals Reports Full Year 2021 Financial Results and Provides Company Highlights Business Wire
Mar-24-22 07:00AM	Infinitum Copper Commences Geophysics Survey At La Adelita Project ACCESSWIRE
Mar-22-22 07:35AM	Infinity Pharmaceuticals Announces the Date of Its Fourth Quarter and Full Year 2021 Financial Results Conference Call and Webcast Business Wire +5.81%
Mar-21-22 08:25AM	Marinus Pharmaceuticals (MRNS) Reports Q4 Loss, Misses Revenue Estimates Zacks -8.12%
Mar-17-22 07:00AM	Infinitum Copper Reports Approval of Options and Adoption of Equity Incentive Plan ACCESSWIRE +9.38%
Mar-09-22 08:35AM	Infinity Pharmaceuticals to Present at the 32nd Annual Oppenheimer Healthcare Conference Business Wire +11.70%
Mar-07-22 05:25PM	Durect (DRRX) Reports Q4 Loss, Tops Revenue Estimates Zacks
Feb-24-22 08:15AM	Ionis Pharmaceuticals (IONS) Q4 Earnings and Revenues Beat Estimates Zacks +9.80%
Feb-01-22 07:03AM	Are Institutions Heavily Invested In Infinity Pharmaceuticals, Inc.'s (NASDAQ:INFI) Shares? Simply Wall St.
Jan-20-22 08:35AM	Infinity Pharmaceuticals to Be Featured in a Fireside Chat as Part of B. Rileys 2022 Virtual Oncology Conference Business Wire
Jan-06-22 08:35AM	Infinity to Present at 40th Annual J.P. Morgan Healthcare Conference Business Wire -10.73%
Jan-05-22 07:05AM	Infinity Pharmaceuticals Outlines Eganelisib Clinical Development Strategy and Provides 2022 Guidance Business Wire -18.24%
Dec-14-21 07:35AM	Infinity Pharmaceuticals Added to the NASDAQ Biotechnology Index Business Wire
Dec-13-21 08:35AM	Infinity Pharmaceuticals to be Featured in B. Riley Fireside Chat Business Wire
Dec-10-21 07:58AM	Encouraging Updated Data from Phase 2 MARIO-3 TNBC Trial Presented at 2021 San Antonio Breast Cancer Symposium Business Wire
Dec-06-21 08:35AM	Infinity Pharmaceuticals to Host an Investor Event on Updated MARIO-3 Data Presented at the 2021 San Antonio Breast Cancer Symposium Business Wire +11.83%
Nov-30-21 06:37AM	Infinity Pharmaceuticals (NASDAQ:INFI) Is In A Good Position To Deliver On Growth Plans Simply Wall St.
Nov-26-21 08:30AM	Are Options Traders Betting on a Big Move in Infinity (INFI) Stock? Zacks
Nov-22-21 08:35AM	Infinity to Present at the Piper Sandler 33rd Annual Virtual Healthcare Conference Business Wire
Nov-02-21 06:15PM	Infinity Pharmaceuticals (INFI) Reports Q3 Loss, Misses Revenue Estimates Zacks
04:05PM	Infinity Pharmaceuticals Reports Third Quarter 2021 Financial Results and Provides Company Update Business Wire
Oct-26-21 07:35AM	Infinity Announces the Date of Its Third Quarter 2021 Financial Results Conference Call and Webcast Business Wire
Oct-18-21 05:22PM	Why Infinity Pharmaceuticals Shot Nearly 4% Higher Today Motley Fool
Oct-01-21 09:27AM	Investors in Infinity Pharmaceuticals (NASDAQ:INFI) have made a stellar return of 195% over the past year Simply Wall St.
Sep-13-21 08:35AM	Infinity to Participate in Oppenheimers Fall Healthcare Life Sciences and MedTech Summit and the 3rd Annual Macrophage-directed Therapies Summit Business Wire
Sep-07-21 07:35AM	Infinity Pharmaceuticals Appoints Robert Ilaria, Jr., M.D., as Chief Medical Officer and Brian Schwartz, M.D., to Its Board of Directors Business Wire
Sep-02-21 08:35AM	Infinity to Participate in Wells Fargo and H.C. Wainwright Investor Conferences Business Wire +6.41%
Aug-23-21 08:32AM	Implied Volatility Surging for Infinity Pharmaceuticals (INFI) Stock Options Zacks +5.96%
Aug-04-21 12:00PM	Infinity Stock Could More Than Double From Here, Says Analyst TipRanks
Aug-03-21 08:00AM	Infinity Pharmaceuticals Reports Inducement Grants to Chief Scientific Officer under Nasdaq Listing Rule 5635(c)(4) Business Wire -9.22%
Aug-02-21 06:07PM	Why Infinity Pharmaceuticals Blasted 38% Higher Today Motley Fool +38.21%
04:06AM	Is Infinity Pharmaceuticals, Inc. (NASDAQ:INFI) Popular Amongst Institutions? Simply Wall St.
Jul-31-21 02:48PM	Infinity: Ball Still in Play for Urothelial Cancer Candidate TipRanks
Jul-28-21 12:05PM	Why Is Infinity Pharmaceuticals Inc (NASDAQ: INFI) The Stock Of The Day? Benzinga +61.18%
Jul-27-21 10:40AM	Infinity Pharma Stock Drops After Updated Data From Bladder & Breast Cancer Trials, Q2 Earnings Benzinga -31.53%
08:45AM	Infinity Pharmaceuticals (INFI) Reports Q2 Loss, Tops Revenue Estimates Zacks
07:31AM	Infinity Pharmaceuticals Presents Updated Data from Phase 2 MARIO-275 Trial in Urothelial Cancer (UC) and Phase 2 MARIO-3 Trial in Triple Negative Breast Cancer (TNBC) Business Wire
07:30AM	Infinity Pharmaceuticals Reports Second Quarter 2021 Financial Results and Provides Company Update Business Wire
05:25AM	Infinity Pharma Reports Positive Results for Cancer Drug Eganelisib and Earnings TheStreet.com
Jul-22-21 03:03PM	Infinity Pharmaceuticals (INFI) May Report Negative Earnings: Know the Trend Ahead of Q2 Release Zacks -6.99%
Jul-20-21 08:35AM	Infinity Pharmaceuticals Hosting Webinar on MARIO-3 and MARIO-275 Phase 2 Trials Business Wire
Jun-14-21 08:35AM	Infinity to Present at The Keystone Symposia Precision Oncology Meeting Business Wire
Jun-03-21 04:39AM	Shareholders May Be More Conservative With Infinity Pharmaceuticals, Inc.'s (NASDAQ:INFI) CEO Compensation For Now Simply Wall St.
May-28-21 04:17AM	We're Not Very Worried About Infinity Pharmaceuticals' (NASDAQ:INFI) Cash Burn Rate Simply Wall St.
May-13-21 06:35PM	Infinity Pharmaceuticals (INFI) Reports Q1 Loss, Tops Revenue Estimates Zacks -5.67%
04:05PM	Infinity Pharmaceuticals Reports First Quarter 2021 Financial Results and Provides Company Update Business Wire
02:30PM	Infinity Pharmaceuticals, Inc. to Host Earnings Call ACCESSWIRE
May-06-21 07:35AM	Infinity Announces the Date of Its First Quarter 2021 Financial Results Conference Call and Webcast Business Wire -5.68%
May-05-21 08:35AM	Infinity to Present at New York Academy of Sciences Frontiers in Cancer Immunotherapy 2021 Business Wire
May-03-21 03:01PM	Infinity Pharmaceuticals (INFI) May Report Negative Earnings: Know the Trend Ahead of Q1 Release Zacks
Apr-27-21 08:35AM	Infinity to Present at the 7th Annual Truist Securities Life Sciences Summit Business Wire
Apr-13-21 08:59AM	FibroGen (FGEN) DMD Drug Pamrevlumab Gets FDA's Fast Track Tag Zacks
Mar-29-21 03:22AM	If You Had Bought Infinity Pharmaceuticals (NASDAQ:INFI) Shares A Year Ago You'd Have Earned 285% Returns Simply Wall St. -7.67%
Mar-19-21 08:47AM	Is the Options Market Predicting a Spike in Infinity (INFI) Stock? Zacks +8.33%
Mar-16-21 05:35PM	Infinity Pharmaceuticals (INFI) Reports Q4 Loss, Tops Revenue Estimates Zacks
04:35PM	Infinity Pharmaceuticals: Q4 Earnings Insights Benzinga
04:05PM	Infinity Pharmaceuticals Reports Full Year 2020 Financial Results and Provides Update on Eganelisib Development Business Wire
02:30PM	Infinity Pharmaceuticals, Inc. to Host Earnings Call ACCESSWIRE
Mar-10-21 08:35AM	Infinity to Present at the Oppenheimer & Co. Annual Healthcare Conference Business Wire
Mar-09-21 04:01PM	Infinity Announces the Date of Its Fourth Quarter and Full Year 2020 Financial Results Conference Call and Webcast Business Wire +9.23%
Mar-02-21 08:35AM	Infinity to Present at the H.C. Wainwright Global Life Sciences Conference Business Wire
Feb-20-21 07:40AM	Your 2 Best Profit Opportunities in 2021 Motley Fool
Feb-18-21 10:02AM	Benzinga's Top Ratings Upgrades, Downgrades For February 18, 2021 Benzinga
08:30AM	Infinity Announces Closing of $92 Million Public Offering of Common Stock Business Wire
Feb-12-21 08:30AM	Infinity Announces Pricing of $80 Million Public Offering of Common Stock Business Wire -9.62%
08:10AM	The Daily Biotech Pulse: European Regulatory Nod For Xeris, Amicus Falls On Data, 4 IPOs, FDA Decision For Mallinckrodt's StrataGraft Delayed Benzinga
Feb-11-21 04:01PM	Infinity Announces Proposed Public Offering of Common Stock Business Wire +13.16%
12:38PM	Why Infinity Pharmaceuticals Is Skyrocketing Today Motley Fool
09:25AM	Infinity Pharmaceuticals to Present at Upcoming BIO CEO & Investor Conference Business Wire
09:16AM	Infinity Pharma Shows Encouraging Eganelisib/Nivolumab Combo Data In Urothelial Cancer Study Benzinga
07:15AM	Infinity Pharmaceuticals Presents Data from Randomized, Placebo-Controlled, Phase 2 MARIO-275 Trial of Eganelisib and Nivolumab in Advanced Urothelial Cancer at ASCO Genitourinary Cancers Symposium Business Wire
Feb-10-21 04:05PM	Infinity Pharmaceuticals Announces Conference Call for the ASCO Genitourinary Cancers Symposium to Discuss Clinical Data from MARIO-275 Phase 2 Study Business Wire -5.73%
Jan-20-21 12:00PM	Here's Why Momentum Investors Will Love Infinity Pharmaceuticals (INFI) Zacks +17.53%
Jan-15-21 08:35AM	Infinity Pharmaceuticals to Participate in B. Riley Securities Virtual Oncology Investor Conference Business Wire +8.16%
Jan-11-21 08:53AM	Implied Volatility Surging for Infinity (INFI) Stock Options Zacks +8.16%
08:05AM	Infinity Pharmaceuticals Announces MARIO-275 Phase 2 Data in Patients with Advanced Urothelial Cancer to be Presented at ASCO Genitourinary Cancers Symposium Business Wire
Jan-07-21 10:51AM	Infinity (INFI) Provides Data on Eganelisib in Urothelial Cancer Zacks +16.02%
08:35AM	Infinity Pharmaceuticals to Participate in Three Investor Conferences This Month Business Wire
Jan-06-21 09:11AM	Infinity Pharmaceuticals Provides Update for Eganelisib in Patients with Metastatic Urothelial Cancer Business Wire
Dec-27-20 02:34AM	Here's What Infinity Pharmaceuticals, Inc.'s (NASDAQ:INFI) Shareholder Ownership Structure Looks Like Simply Wall St.
Dec-09-20 12:25PM	Why Sorrento And Infinity Are Moving Today Benzinga -19.13%
09:10AM	Infinity Pharmaceuticals Presents Front-Line Triple Negative Breast Cancer Data from Ongoing Phase 2 MARIO-3 Trial at the 2020 San Antonio Breast Cancer Symposium Business Wire
Dec-07-20 07:35AM	Infinity Pharmaceuticals Announces Conference Call for the 2020 San Antonio Breast Cancer Symposium Business Wire
Dec-02-20 09:47PM	Is Infinity Pharmaceuticals Inc. (INFI) A Bargain? Insider Monkey
Nov-17-20 09:22AM	Infinity Pharmaceuticals Announces Presentations at the 2020 San Antonio Breast Cancer Symposium Business Wire -5.43%
Nov-12-20 05:53AM	Earnings Update: Infinity Pharmaceuticals, Inc. (NASDAQ:INFI) Just Reported And Analysts Are Boosting Their Estimates Simply Wall St.
Nov-09-20 06:35PM	Infinity Pharmaceuticals (INFI) Reports Q3 Loss, Tops Revenue Estimates Zacks
05:14PM	Recap: Infinity Pharmaceuticals Q3 Earnings Benzinga

Infinity Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing novel medicines for people with cancer. Its product candidate is IPI-549, an orally administered clinical-stage immuno-oncology product candidate that inhibits the enzyme phosphoinositide-3-kinase-gamma, which is in Phase 2 clinical trials for the treatment of metastatic triple negative breast cancer and urothelial cancer; and Phase 1/1b clinical trials for the treatment of solid tumors. The company has strategic alliances with Intellikine, Inc. to discover, develop, and commercialize pharmaceutical products targeting the delta and/or gamma isoforms of PI3K; Verastem, Inc. to research, develop, commercialize, and manufacture duvelisib and products containing duvelisib; and PellePharm, Inc. to develop and commercialize rights to its hedgehog inhibitor program, IPI-926, a clinical-stage product candidate, as well as collaboration agreements with Arcus Biosciences, Inc., F. Hoffmann-La Roche Ltd., and Bristol Myers Squibb Company. Infinity Pharmaceuticals, Inc. was incorporated in 1995 and is headquartered in Cambridge, Massachusetts.

open in yahoo | open in reuters | open in marketwatch | open in google

Upgrade your FINVIZ experience